MRI with Gadolinium-Based Nanoparticles - Nanotechnology for Biomedical Imaging and Diagnostics - page 244

[23] Werner eJ, Botta M, Aime s, Raymond Kn. effect of a mesitylene-based ligand cap on
the relaxometric properties of Gd(III) hydroxypyridonate MRI contrast agents. Contrast
Media Mol Imaging 2009; 4 :220-229.
[24] Hermann p, Kotek J, Kubicek V, Lukes I. Gadolinium(iii) complexes as MRI contrast
agents: ligand design and properties of the complexes. dalton Trans 2008; 23 :3027-3047.
[25] Jacques V, dumas s, sun W-C, Troughton Js, Greenfield MT, Caravan p. High-relaxivity
magnetic resonance imaging contrast agents part 2: optimization of inner- and second-
sphere relaxivity. Invest Radiol 2010; 45 :613-624.
[26] Vitha T, Kubicek V, Kotek J, Hermann p, Vander elst L, Muller Rn, Lukes I, peters JA.
Gd(iii) complex of a monophosphinate-bis(phosphonate) dOTA analogue with a high
relaxivity; Lanthanide(iii) complexes for imaging and radiotherapy of calcified tissues.
dalton Trans 2009; 17 :3204-3214.
[27] Lebduskova p, sour A, Helm L, Toth e, Kotek J, Lukes I, Merbach Ae. phosphinic
derivative of dTpA conjugated to a G5 pAMAM dendrimer: an 17O and 1H relaxation
study of its Gd(iii) complex. dalton Trans 2006; 28 :3399-3406.
[28] dumas s, Jacques V, sun W-C, Troughton Js, Welch JT, Chasse JM, schmitt-Willich H,
Caravan p. High relaxivity magnetic resonance imaging contrast agents part 1: impact of
single donor atom substitution on relaxivity of serum albumin-bound gadolinium
complexes. Invest Radiol 2010; 45 :600-612.
[29] Tei L, Botta M, Lovazzano C, Barge A, Milone L, Aime s. 1H and 17O nMR relaxomet-
ric study in aqueous solution of Gd(III) complexes of eGTA-like derivatives bearing
methylenephosphonic groups. Magn Reson Chem 2008; 46 :s86-s93.
[30] Caravan p, Greenfield MT, Li X, sherry Ad. The Gd3+ complex of a fatty acid analogue
of dOTp binds to multiple albumin sites with variable water relaxivities. Inorg Chem
2001; 40 :6580-6587.
[31] Fulton dA, elemento eM, Aime s, Chaabane L, Botta M, parker d. Glycoconjugates of
gadolinium complexes for MRI applications. Chem Commun (Camb) 2006; 10 :1064-1066.
[32] Rudovsky J, Kotek J, Hermann p, Lukes I, Mainero V, Aime s. synthesis of a bifunc-
tional monophosphinic acid dOTA analogue ligand and its lanthanide(iii) complexes.
A gadolinium(iii) complex endowed with an optimal water exchange rate for MRI
applications. Org Biomol Chem 2005; 3 :112-117.
[33] Tallec G, Fries pH, Imbert d, Mazzanti M. High relaxivity and stability of a hydroxy-
quinolinate-based tripodal monoaquagadolinium complex for use as a bimodal MRI/
optical imaging agent. Inorg Chem 2011; 50 :7943-7945.
[34] Caravan p, Cloutier nJ, Greenfield MT, Mcdermid sA, dunham su, Bulte JWM,
Amedio JC, Looby RJ, supkowski RM, Horrocks Wd, McMurry TJ, Lauffer RB. The
interaction of Ms-325 with human serum albumin and its effect on proton relaxation
rates. J Am Chem soc 2002; 124 :3152-3162.
[35] Goyen M. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk
Manag 2008; 4 :1.
[36] Grossman RI, Rubin dL, Hunter G, Haughton VM, Lee d, sze G, Kuhn MJ, Maravilla K,
Tu R, Heindel W, Wippold JI, Leeds n, Zelch J, Jinkins JR, Grodd W, Truwit C, Kanal
e, provenzale JM, Ramsey R, simon J, Brunberg JA, stevens GR, Kristy RM.
Magnetic resonance imaging in patients with central nervous system pathology: a
comparison of OptiMARK (Gd-dTpA-BMeA) and magnevist (Gd-dTpA). Invest
Radiol 2000; 35 :412-419.